ArticleFrontiers in surgery2025
Case Report: Clinical application of hyperbaric oxygen therapy after bladder fistula repair surgery: a report of 7 cases and literature review.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperbaric oxygen treatment (HBOT) is a therapeutic modality that delivers 100% oxygen under supra-atmospheric pressure, which has been widely used in the clinical management of various diseases. The incidence of genitourinary fistulas is relatively low in developed countries, mainly presenting as complications of gynecological surgeries, while it remains high in developing nations due to factors such as prolonged labor and inadequate medical care. Among these, bladder fistula is the most common type of genitourinary fistula. This article presents the outcomes of 7 patients who received HBOT after bladder fistula repair surgery, including 6 cases of vesicovaginal fistula (VVF) and 1 case of colovesical fistula (CVF). HBOT was initiated on the first postoperative day, administered once daily for a total of 10 consecutive days, and no relevant adverse reactions occurred in any patient during the HBOT course. All patients achieved uneventful postoperative recovery and were discharged from the hospital, with no recurrence of symptoms observed during the 3-12 months of follow-up. As a novel adjunctive therapy for patients after bladder fistula surgery, HBOT exhibits satisfactory preliminary efficacy and favorable safety profile, yet further research with expanded sample size and in-depth investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.